Kazia Therapeutics Ltd (KZIA) ADR Each Representing 100 Ord Shares SPON
Sell:$0.77Buy:$0.83
$0.01
(1.85%)
- This stock can be held in a
Stocks and Shares ISA
SIPP$0.01
(1.85%)$0.01
(1.85%)Company Information
About this company
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Key people
Key facts
- EPICKZIA
- LocationAustralia
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS48669G2049
- Market cap$5.07m
- Employees12
- Shares in issue22.80m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.